Wednesday, September 14, 2016 4:43:31 AM
ku, the facts are that Avid is a successful revenue generator and that the clinical program of PPHM R&D has been redesigned.
I was 100% for tring to go it alone before Sunrise stopped. With Chemo+Bavi that option was certainly possible, while possibly not the most lucrative certainly the fasted way to big revenue during 3-5 years until IO takes over completely. PPHM needs only commercial Bavi production in a small condition and the leverage on Bavi when Avid produces it is so high that in no time they will have several hundred million dollar on the bank. At 30K per treatment only 1250 treatments generate the same revenue as a complete TOP year at Avid I.
Even after ASCO 2013, where IO suddenly surfaced, I still believed in chemo+bavi and a go it alone because no matter what delay damage the 'dose switching' did we were still in time. However as the following months after ASCO the steam was set on IO (mostly BMY/Merck), and later with the stop of Sunrise, the go it alone was over and out. PPHM knows this and adapts to the new situation.
We are now in an on-term more lucrative path BUT we pay in time/delay to market/waiting... But if PPHM plays this right, see my post on the subject after Sunrise stop, they are going to do even better with the new scenario. That at the same time their revenue of manufacturing increases vs draining all funding out of the ATM is a positive thing in my book.
People first curs the ATM then when we get the funding revenue from manufacturing we suddenly are a manufacturing company.
Maybe a look at the agenda that cj posted in relation to presentations and "who" is involved (including MSK - Wolchok , Rutger's - Birge) and the research deals with NCCN/MSK, the involvement of AstraZeneac with Durvalumab and Merck with Keytruda in new trials all show that we are not a manufacturing company but that manufacturing is a good diversification that brings funding revenue, lowers risks such as BK, and before all puts us out of the risks of bankers with their expensive loans and dangerous related terms.
Many will HATE it that PPHM/Avid are becoming self supporting because that will lower the external grip on them. Good for us because the external factors are/were the main problem.
I was 100% for tring to go it alone before Sunrise stopped. With Chemo+Bavi that option was certainly possible, while possibly not the most lucrative certainly the fasted way to big revenue during 3-5 years until IO takes over completely. PPHM needs only commercial Bavi production in a small condition and the leverage on Bavi when Avid produces it is so high that in no time they will have several hundred million dollar on the bank. At 30K per treatment only 1250 treatments generate the same revenue as a complete TOP year at Avid I.
Even after ASCO 2013, where IO suddenly surfaced, I still believed in chemo+bavi and a go it alone because no matter what delay damage the 'dose switching' did we were still in time. However as the following months after ASCO the steam was set on IO (mostly BMY/Merck), and later with the stop of Sunrise, the go it alone was over and out. PPHM knows this and adapts to the new situation.
We are now in an on-term more lucrative path BUT we pay in time/delay to market/waiting... But if PPHM plays this right, see my post on the subject after Sunrise stop, they are going to do even better with the new scenario. That at the same time their revenue of manufacturing increases vs draining all funding out of the ATM is a positive thing in my book.
People first curs the ATM then when we get the funding revenue from manufacturing we suddenly are a manufacturing company.
Maybe a look at the agenda that cj posted in relation to presentations and "who" is involved (including MSK - Wolchok , Rutger's - Birge) and the research deals with NCCN/MSK, the involvement of AstraZeneac with Durvalumab and Merck with Keytruda in new trials all show that we are not a manufacturing company but that manufacturing is a good diversification that brings funding revenue, lowers risks such as BK, and before all puts us out of the risks of bankers with their expensive loans and dangerous related terms.
Many will HATE it that PPHM/Avid are becoming self supporting because that will lower the external grip on them. Good for us because the external factors are/were the main problem.
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
